BioInsights - BioInsights

CELL AND GENE THERAPY INSIGHTS

April 2023 Issue

Vol 9 Issue 3

Vector bioprocessing & raw materials

Featuring this month's spotlight content:

Vector bioprocessing & raw materials
View
Cell and Gene Therapy Insights Vol 9 Issue 3
View

Latest Articles

Opportunities to implement continuous processing in production of recombinant adeno-associated viral vectors

Opportunities to implement continuous processing in production of recombinant adeno-associated viral vectors

G Thakur, S Mink, H Bak et al.
18 September
Commentary
Increase quality & standardization of cellular starting material

Increase quality & standardization of cellular starting material

Matt Hemstreet
31 August
FastFacts
RNA: the next era in therapeutic development

RNA: the next era in therapeutic development

31 August
EBook
A large-scale lentivirus manufacturing platform to accelerate time to clinic

A large-scale lentivirus manufacturing platform to accelerate time to clinic

Brian Mullan
31 August
FastFacts
At the cutting edge of AAV capsid engineering

At the cutting edge of AAV capsid engineering

Eric Kelsic, Adrian Veres
31 May
Interview
Non-viral methods for <em>ex vivo</em> cell & gene therapy: is the future non-viral?

Non-viral methods for ex vivo cell & gene therapy: is the future non-viral?

Valeria Annibaldi, Andrea Toell
30 May
Podcast
Utilizing AI to drive AAV-based gene delivery to the CNS

Utilizing AI to drive AAV-based gene delivery to the CNS

David Huss
29 May
Interview
Cell culture in immune cell therapies: do more with less

Cell culture in immune cell therapies: do more with less

A Smith, J Ludwig, D Hermanson
29 May
Expert Roundtable
Quantifying manufacturing uncertainty and developing digital tools for supply chain optimization

Quantifying manufacturing uncertainty and developing digital tools for supply chain optimization

Maria Papathanasiou
22 May
Interview

Channel content

Designing viral vector clearance studies for CGT products according to ICH Q5A (R2): part 1

Designing viral vector clearance studies for CGT products according to ICH Q5A (R2): part 1

Tareq Jaber
19 May
FastFacts
Designing viral clearance studies for CGT products according to ICH Q5A (R2): part 2

Designing viral clearance studies for CGT products according to ICH Q5A (R2): part 2

Tareq Jaber
19 May
FastFacts
Navigating evolving regulatory CMC guidance in the AAV gene therapy field

Navigating evolving regulatory CMC guidance in the AAV gene therapy field

M Brewer, A Cockroft, C Fuentes et al.
15 May
Expert Roundtable
View channel
Opportunities to implement continuous processing in production of recombinant adeno-associated viral vectors

Opportunities to implement continuous processing in production of recombinant adeno-associated viral vectors

G Thakur, S Mink, H Bak et al.
18 September
Commentary
RNA: the next era in therapeutic development

RNA: the next era in therapeutic development

31 August
EBook
Increase quality & standardization of cellular starting material

Increase quality & standardization of cellular starting material

Matt Hemstreet
31 August
FastFacts
View channel
Opportunities to implement continuous processing in production of recombinant adeno-associated viral vectors

Opportunities to implement continuous processing in production of recombinant adeno-associated viral vectors

G Thakur, S Mink, H Bak et al.
18 September
Commentary
A large-scale lentivirus manufacturing platform to accelerate time to clinic

A large-scale lentivirus manufacturing platform to accelerate time to clinic

Brian Mullan
31 August
FastFacts
At the cutting edge of AAV capsid engineering

At the cutting edge of AAV capsid engineering

Eric Kelsic, Adrian Veres
31 May
Interview
View channel
Designing viral vector clearance studies for CGT products according to ICH Q5A (R2): part 1

Designing viral vector clearance studies for CGT products according to ICH Q5A (R2): part 1

Tareq Jaber
19 May
FastFacts
Designing viral clearance studies for CGT products according to ICH Q5A (R2): part 2

Designing viral clearance studies for CGT products according to ICH Q5A (R2): part 2

Tareq Jaber
19 May
FastFacts
Navigating evolving regulatory CMC guidance in the AAV gene therapy field

Navigating evolving regulatory CMC guidance in the AAV gene therapy field

M Brewer, A Cockroft, C Fuentes et al.
15 May
Expert Roundtable
View channel
Increase quality & standardization of cellular starting material

Increase quality & standardization of cellular starting material

Matt Hemstreet
31 August
FastFacts
Quantifying manufacturing uncertainty and developing digital tools for supply chain optimization

Quantifying manufacturing uncertainty and developing digital tools for supply chain optimization

Maria Papathanasiou
22 May
Interview
Sustainable plasmid DNA strategies, achieving streamlined secure supply to clinic & commercialization

Sustainable plasmid DNA strategies, achieving streamlined secure supply to clinic & commercialization

Andrew Frazer, Amanda Weiss
26 April
Innovator Insight
View channel
At the cutting edge of AAV capsid engineering

At the cutting edge of AAV capsid engineering

Eric Kelsic, Adrian Veres
31 May
Interview
Utilizing AI to drive AAV-based gene delivery to the CNS

Utilizing AI to drive AAV-based gene delivery to the CNS

David Huss
29 May
Interview
Assessing recent milestones in AAV capsid discovery & development for CNS applications

Assessing recent milestones in AAV capsid discovery & development for CNS applications

Mathieu Nonnenmacher
9 May
Interview
View channel
A payment innovation framework to meet the urgent need in advanced therapies

A payment innovation framework to meet the urgent need in advanced therapies

Mark Trusheim
17 April
Interview
Funding the future: cell & gene therapy development

Funding the future: cell & gene therapy development

Nick Meyers, Neil Fish
28 March
Viewpoint
View channel